{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:16:24Z","timestamp":1791558984323,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["DNA Repair"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.dnarep.2025.103857","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T02:48:50Z","timestamp":1749782930000},"page":"103857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing"],"prefix":"10.1016","volume":"152","author":[{"given":"Hongxiu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dnarep.2025.103857_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.dnarep.2025.103857_bib2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.dnarep.2025.103857_bib3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.dnarep.2025.103857_bib4","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1093\/oncolo\/oyad053","article-title":"Impact of treatment sequencing on overall survival in patients with transplant-ineligible newly diagnosed myeloma","volume":"28","author":"Fonseca","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.dnarep.2025.103857_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-025-01639-5","article-title":"Current state of evidence on definitions and management of high-risk multiple myeloma","author":"Mohan Lal","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.dnarep.2025.103857_bib6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.trecan.2020.05.006","article-title":"Genomic instability in multiple myeloma","volume":"6","author":"Alagpulinsa","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.dnarep.2025.103857_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.dnarep.2025.103857_bib8","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.dnarep.2025.103857_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood.2023021384","article-title":"Myeloma and DNA damage","volume":"143","author":"Tonon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.dnarep.2025.103857_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.dnarep.2025.103857_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.dnarep.2025.103857_bib12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.dnarep.2025.103857_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","volume":"22","author":"Maeser","year":"2021","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.dnarep.2025.103857_bib14","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.omtn.2022.01.018","article-title":"Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC","volume":"27","author":"Liu","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.dnarep.2025.103857_bib15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2011.94","article-title":"Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX","volume":"25","author":"Walters","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.dnarep.2025.103857_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-019-0221-9","article-title":"Mutational processes contributing to the development of multiple myeloma","volume":"9","author":"Hoang","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.dnarep.2025.103857_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216594","article-title":"Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma","volume":"582","author":"Hong","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.dnarep.2025.103857_bib18","article-title":"Targeting DNA damage response and immune checkpoint for anticancer therapy","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.dnarep.2025.103857_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.dnarep.2025.103857_bib20","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.gendis.2022.05.020","article-title":"A new emerging target in cancer immunotherapy: galectin-9 (LGALS9)","volume":"10","author":"Lv","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.dnarep.2025.103857_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2288481","article-title":"Activated Tim-3\/Galectin-9 participated in the development of multiple myeloma by negatively regulating CD4 T cells","volume":"29","author":"Zhang","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.dnarep.2025.103857_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2010.25","article-title":"Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways","volume":"24","author":"Kobayashi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.dnarep.2025.103857_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.104008","article-title":"B7-H4, a promising target for immunotherapy","volume":"347","author":"Wang","year":"2020","journal-title":"Cell Immunol."},{"key":"10.1016\/j.dnarep.2025.103857_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bbrc.2015.02.098","article-title":"Cancer cell-associated cytoplasmic B7-H4 is induced by hypoxia through hypoxia-inducible factor-1\u03b1 and promotes cancer cell proliferation","volume":"459","author":"Jeon","year":"2015","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.dnarep.2025.103857_bib25","doi-asserted-by":"crossref","first-page":"13229","DOI":"10.18632\/oncotarget.3644","article-title":"Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma","volume":"6","author":"Cowan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.dnarep.2025.103857_bib26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/EDBK_200879","article-title":"Risk stratification and targets in multiple myeloma: from genomics to the bedside","volume":"38","author":"Perrot","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.dnarep.2025.103857_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030666","article-title":"KRAS and RAS-MAPK pathway deregulation in mature B cell lymphoproliferative disorders","volume":"14","author":"Vendramini","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.dnarep.2025.103857_bib28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/leu.2015.208","article-title":"Inhibiting MEK in MAPK pathway-activated myeloma","volume":"30","author":"Heuck","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.dnarep.2025.103857_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5483\/BMBRep.2019.52.2.213","article-title":"High expression of RAD51 promotes DNA damage repair and survival in KRAS-mutant lung cancer cells","volume":"52","author":"Hu","year":"2019","journal-title":"BMB Rep."},{"key":"10.1016\/j.dnarep.2025.103857_bib30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.dnarep.2025.103857_bib31","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \"BRCAness\" sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.dnarep.2025.103857_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/039463200401700107","article-title":"Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity","volume":"17","author":"Alexandrakis","year":"2004","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.dnarep.2025.103857_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094717","article-title":"Blocking the PCNA\/NKp44 checkpoint to stimulate NK cell responses to multiple myeloma","volume":"23","author":"Iraqi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.dnarep.2025.103857_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2023.194925","article-title":"The moonlighting of RAD23 in DNA repair and protein degradation","volume":"1866","author":"Gr\u00f8nb\u00e6k-Thygesen","year":"2023","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"10.1016\/j.dnarep.2025.103857_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2016.10.027","article-title":"Two mammalian homologs of yeast Rad23, HR23A and HR23B, as multifunctional proteins","volume":"597","author":"Yokoi","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.dnarep.2025.103857_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-025-02295-w","article-title":"Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.dnarep.2025.103857_bib37","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1038\/s41467-020-16443-x","article-title":"The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.dnarep.2025.103857_bib38","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/2159-8290.CD-20-0163","article-title":"Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1\/2- and non-BRCA1\/2-mutant cancers","volume":"10","author":"Yap","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2025.103857_bib39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2025.103857_bib40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2025.103857_bib41","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","article-title":"mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer","volume":"22","author":"Mo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.dnarep.2025.103857_bib42","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-12-0433","article-title":"The promise of combining inhibition of PI3K and PARP as cancer therapy","volume":"2","author":"Rehman","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2025.103857_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.dnarep.2025.103857_bib44","article-title":"Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.dnarep.2025.103857_bib45","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/s41375-022-01536-x","article-title":"In vivo anti-tumor effect of PARP inhibition in IDH1\/2 mutant MDS\/AML resistant to targeted inhibitors of mutant IDH1\/2","volume":"36","author":"Gbyli","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.dnarep.2025.103857_bib46","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 mutations sensitize acute myeloid leukemia to PARp inhibition and this is reversed by IDH1\/2-mutant inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.dnarep.2025.103857_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246228","article-title":"Hyperthermia as a potential cornerstone of effective multimodality treatment with radiotherapy, cisplatin and PARP inhibitor in IDH1-mutated cancer cells","volume":"14","author":"Khurshed","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.dnarep.2025.103857_bib48","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.dnarep.2025.103857_bib49","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1124\/jpet.112.200832","article-title":"The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","volume":"344","author":"Spurgeon","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.dnarep.2025.103857_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042193","article-title":"Roles and regulation of BCL-xL in hematological malignancies","volume":"23","author":"Morales-Mart\u00ednez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.dnarep.2025.103857_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41375-021-01347-6","article-title":"Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma","volume":"36","author":"Rossi","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.dnarep.2025.103857_bib52","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.dnarep.2025.103857_bib53","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1021\/acsptsci.0c00201","article-title":"Comparative activity and off-target effects in cells of the CHK1 inhibitors MK-8776, SRA737, and LY2606368","volume":"4","author":"Ditano","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.dnarep.2025.103857_bib54","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/neuonc\/nou058","article-title":"Role of AKT signaling in DNA repair and clinical response to cancer therapy","volume":"16","author":"Liu","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.dnarep.2025.103857_bib55","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.4161\/15384047.2014.961876","article-title":"Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1","volume":"15","author":"Duan","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.dnarep.2025.103857_bib56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13058-021-01408-9","article-title":"An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer","volume":"23","author":"Stringer-Reasor","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.dnarep.2025.103857_bib57","series-title":"Probe Reports from the NIH Molecular Libraries Program","article-title":"Discovery of ML323 as a novel inhibitor of the USP1\/UAF1 deubiquitinase complex","author":"Dexheimer","year":"2010"}],"container-title":["DNA Repair"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568786425000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568786425000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T07:20:11Z","timestamp":1779607211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568786425000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":57,"alternative-id":["S1568786425000539"],"URL":"https:\/\/doi.org\/10.1016\/j.dnarep.2025.103857","relation":{},"ISSN":["1568-7864"],"issn-type":[{"value":"1568-7864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing","name":"articletitle","label":"Article Title"},{"value":"DNA Repair","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dnarep.2025.103857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103857"}}